164 related articles for article (PubMed ID: 18781824)
1. Inhibiting angiotensin type 1 receptors as a target for diabetes.
Kintscher U; Foryst-Ludwig A; Unger T
Expert Opin Ther Targets; 2008 Oct; 12(10):1257-63. PubMed ID: 18781824
[TBL] [Abstract][Full Text] [Related]
2. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
4. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
5. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
7. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
8. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
Suksomboon N; Poolsup N; Prasit T
J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583
[TBL] [Abstract][Full Text] [Related]
10. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
11. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle.
Henriksen EJ; Prasannarong M
Mol Cell Endocrinol; 2013 Sep; 378(1-2):15-22. PubMed ID: 22564510
[TBL] [Abstract][Full Text] [Related]
12. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials.
Stojiljkovic L; Behnia R
Curr Pharm Des; 2007; 13(13):1335-45. PubMed ID: 17506719
[TBL] [Abstract][Full Text] [Related]
13. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
Kintscher U; Unger T
Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
[TBL] [Abstract][Full Text] [Related]
14. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
15. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
16. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Kurtz TW; Pravenec M
J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
[TBL] [Abstract][Full Text] [Related]
19. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
McFarlane SI
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1363-71. PubMed ID: 19900019
[TBL] [Abstract][Full Text] [Related]
20. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
